vs
百特国际（BAX）与新美亚（SANM）财务数据对比。点击上方公司名可切换其他公司
新美亚的季度营收约是百特国际的1.1倍（$3.2B vs $3.0B），新美亚净利率更高（1.5% vs -37.9%，领先39.5%），百特国际同比增速更快（458.0% vs 59.0%），过去两年新美亚的营收复合增速更高（31.9% vs -9.0%）
百特国际是总部位于美国伊利诺伊州迪尔菲尔德的跨国医疗健康企业，业务布局覆盖全球众多市场，专注于研发、生产及销售各类医疗相关产品与解决方案，为全球医疗机构和患者提供专业可靠的医疗支持。
新美亚公司是总部位于美国加利福尼亚州圣何塞的电子制造服务（EMS）提供商，服务通信、计算机硬件领域的原始设备制造商（OEM）。集团拥有近80个生产基地，是全球规模最大的印刷电路板和背板独立制造商之一，2022年位列《财富》世界500强第482位。
BAX vs SANM — 直观对比
营收规模更大
SANM
是对方的1.1倍
$3.0B
营收增速更快
BAX
高出399.0%
59.0%
净利率更高
SANM
高出39.5%
-37.9%
两年增速更快
SANM
近两年复合增速
-9.0%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $3.0B | $3.2B |
| 净利润 | $-1.1B | $49.3M |
| 毛利率 | 19.4% | 7.6% |
| 营业利润率 | -24.5% | 2.3% |
| 净利率 | -37.9% | 1.5% |
| 营收同比 | 458.0% | 59.0% |
| 净利润同比 | -120.3% | -24.2% |
| 每股收益（稀释后） | $-2.21 | $0.89 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BAXSANM
| Q4 25 | $3.0B | $3.2B | ||
| Q3 25 | $2.8B | $2.1B | ||
| Q2 25 | $2.8B | $2.0B | ||
| Q1 25 | $2.6B | $2.0B | ||
| Q4 24 | $533.0M | $2.0B | ||
| Q3 24 | $2.7B | $2.0B | ||
| Q2 24 | $3.8B | $1.8B | ||
| Q1 24 | $3.6B | $1.8B |
净利润BAXSANM
| Q4 25 | $-1.1B | $49.3M | ||
| Q3 25 | $-46.0M | $48.1M | ||
| Q2 25 | $91.0M | $68.6M | ||
| Q1 25 | $126.0M | $64.2M | ||
| Q4 24 | $-512.0M | $65.0M | ||
| Q3 24 | $140.0M | $61.4M | ||
| Q2 24 | $-314.0M | $51.6M | ||
| Q1 24 | $37.0M | $52.5M |
毛利率BAXSANM
| Q4 25 | 19.4% | 7.6% | ||
| Q3 25 | 33.5% | 9.1% | ||
| Q2 25 | 35.3% | 8.9% | ||
| Q1 25 | 32.8% | 8.9% | ||
| Q4 24 | 25.0% | 8.4% | ||
| Q3 24 | 38.3% | 8.5% | ||
| Q2 24 | 37.5% | 8.3% | ||
| Q1 24 | 38.6% | 8.4% |
营业利润率BAXSANM
| Q4 25 | -24.5% | 2.3% | ||
| Q3 25 | 6.1% | 3.7% | ||
| Q2 25 | 6.8% | 4.7% | ||
| Q1 25 | 2.2% | 4.6% | ||
| Q4 24 | -25.5% | 4.4% | ||
| Q3 24 | 5.7% | 4.4% | ||
| Q2 24 | -5.0% | 4.5% | ||
| Q1 24 | 5.2% | 4.1% |
净利率BAXSANM
| Q4 25 | -37.9% | 1.5% | ||
| Q3 25 | -1.6% | 2.3% | ||
| Q2 25 | 3.2% | 3.4% | ||
| Q1 25 | 4.8% | 3.2% | ||
| Q4 24 | -96.1% | 3.2% | ||
| Q3 24 | 5.2% | 3.0% | ||
| Q2 24 | -8.2% | 2.8% | ||
| Q1 24 | 1.0% | 2.9% |
每股收益（稀释后）BAXSANM
| Q4 25 | $-2.21 | $0.89 | ||
| Q3 25 | $-0.09 | $0.88 | ||
| Q2 25 | $0.18 | $1.26 | ||
| Q1 25 | $0.25 | $1.16 | ||
| Q4 24 | $-0.99 | $1.16 | ||
| Q3 24 | $0.27 | $1.09 | ||
| Q2 24 | $-0.62 | $0.91 | ||
| Q1 24 | $0.07 | $0.93 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.0B | $1.4B |
| 总债务越低越好 | $9.5B | $2.2B |
| 股东权益账面价值 | $6.1B | $2.7B |
| 总资产 | $20.1B | $9.8B |
| 负债/权益比越低杠杆越低 | 1.55× | 0.82× |
8季度趋势，按日历期对齐
现金及短期投资BAXSANM
| Q4 25 | $2.0B | $1.4B | ||
| Q3 25 | $1.7B | $926.3M | ||
| Q2 25 | $1.7B | $797.9M | ||
| Q1 25 | $2.3B | $647.1M | ||
| Q4 24 | $1.8B | $642.4M | ||
| Q3 24 | $1.4B | $625.9M | ||
| Q2 24 | $2.1B | $657.7M | ||
| Q1 24 | $3.0B | $650.9M |
总债务BAXSANM
| Q4 25 | $9.5B | $2.2B | ||
| Q3 25 | — | $300.5M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $10.4B | — | ||
| Q3 24 | $10.4B | — | ||
| Q2 24 | $10.4B | — | ||
| Q1 24 | $11.1B | — |
股东权益BAXSANM
| Q4 25 | $6.1B | $2.7B | ||
| Q3 25 | $7.2B | $2.5B | ||
| Q2 25 | $7.3B | $2.5B | ||
| Q1 25 | $7.1B | $2.4B | ||
| Q4 24 | $7.0B | $2.4B | ||
| Q3 24 | $7.9B | $2.4B | ||
| Q2 24 | $7.6B | $2.3B | ||
| Q1 24 | $8.2B | $2.3B |
总资产BAXSANM
| Q4 25 | $20.1B | $9.8B | ||
| Q3 25 | $21.1B | $5.9B | ||
| Q2 25 | $21.0B | $5.2B | ||
| Q1 25 | $21.3B | $5.0B | ||
| Q4 24 | $25.8B | $4.8B | ||
| Q3 24 | $26.7B | $4.8B | ||
| Q2 24 | $26.3B | $4.7B | ||
| Q1 24 | $27.8B | $4.7B |
负债/权益比BAXSANM
| Q4 25 | 1.55× | 0.82× | ||
| Q3 25 | — | 0.12× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.49× | — | ||
| Q3 24 | 1.33× | — | ||
| Q2 24 | 1.37× | — | ||
| Q1 24 | 1.36× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $584.0M | $178.7M |
| 自由现金流经营现金流 - 资本支出 | — | $91.9M |
| 自由现金流率自由现金流/营收 | — | 2.9% |
| 资本支出强度资本支出/营收 | — | 2.7% |
| 现金转化率经营现金流/净利润 | — | 3.63× |
| 过去12个月自由现金流最近4个季度 | — | $518.3M |
8季度趋势，按日历期对齐
经营现金流BAXSANM
| Q4 25 | $584.0M | $178.7M | ||
| Q3 25 | $237.0M | $199.1M | ||
| Q2 25 | $217.0M | $200.8M | ||
| Q1 25 | $-193.0M | $156.9M | ||
| Q4 24 | $488.0M | $63.9M | ||
| Q3 24 | $253.0M | $51.9M | ||
| Q2 24 | $115.0M | $90.0M | ||
| Q1 24 | $163.0M | $72.3M |
自由现金流BAXSANM
| Q4 25 | — | $91.9M | ||
| Q3 25 | — | $136.6M | ||
| Q2 25 | — | $163.7M | ||
| Q1 25 | — | $126.1M | ||
| Q4 24 | — | $46.9M | ||
| Q3 24 | — | $27.2M | ||
| Q2 24 | — | $67.2M | ||
| Q1 24 | — | $42.7M |
自由现金流率BAXSANM
| Q4 25 | — | 2.9% | ||
| Q3 25 | — | 6.5% | ||
| Q2 25 | — | 8.0% | ||
| Q1 25 | — | 6.4% | ||
| Q4 24 | — | 2.3% | ||
| Q3 24 | — | 1.4% | ||
| Q2 24 | — | 3.7% | ||
| Q1 24 | — | 2.3% |
资本支出强度BAXSANM
| Q4 25 | — | 2.7% | ||
| Q3 25 | — | 3.0% | ||
| Q2 25 | — | 1.8% | ||
| Q1 25 | — | 1.5% | ||
| Q4 24 | — | 0.9% | ||
| Q3 24 | — | 1.2% | ||
| Q2 24 | — | 1.2% | ||
| Q1 24 | — | 1.6% |
现金转化率BAXSANM
| Q4 25 | — | 3.63× | ||
| Q3 25 | — | 4.14× | ||
| Q2 25 | 2.38× | 2.93× | ||
| Q1 25 | -1.53× | 2.44× | ||
| Q4 24 | — | 0.98× | ||
| Q3 24 | 1.81× | 0.85× | ||
| Q2 24 | — | 1.74× | ||
| Q1 24 | 4.41× | 1.38× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BAX
| Other | $1.5B | 51% |
| Infusion Therapies And Technologies | $543.0M | 18% |
| Pharmaceutical Compounding | $316.0M | 11% |
| Front Line Care | $219.0M | 7% |
| Injectables And Anesthesia | $190.0M | 6% |
| Advanced Surgery | $177.0M | 6% |
SANM
| Industrial And Energy Medical Defense And Aerospace And Automotive And Transportation | $1.2B | 38% |
| ZT Systems | $1.1B | 34% |
| Other Segments CPS | $434.3M | 14% |
| CPS Third Party Revenue | $412.7M | 13% |
| Change In Accounting Method Accounted For As Change In Estimate | $2.7M | 0% |
